ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
BI, Lilly announces results of new post-hoc analysis of data from the EMPA-REG OUTCOME trial
June 18, 2019In this new post-hoc analysis, the effect of empagliflozin on reducing the risk of cardiovascular and kidney outcomes was consistent between people in the EMPA-REG OUTCOME trial who had chronic kidney disease without overt proteinuria and all others in th
Pharma Sources Insight January 2025
